HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis

NASDAQ:HRMY • US4131971040

29.16 USD
-5.23 (-15.21%)
At close: Feb 20, 2026
30.28 USD
+1.12 (+3.84%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

8

Overall HRMY gets a fundamental rating of 8 out of 10. We evaluated HRMY against 191 industry peers in the Pharmaceuticals industry. HRMY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: HRMY is growing strongly while it also seems undervalued. These ratings would make HRMY suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year HRMY was profitable.
  • In the past year HRMY had a positive cash flow from operations.
  • HRMY had positive earnings in 4 of the past 5 years.
  • HRMY had a positive operating cash flow in 4 of the past 5 years.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

  • With an excellent Return On Assets value of 15.37%, HRMY belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
  • With an excellent Return On Equity value of 22.23%, HRMY belongs to the best of the industry, outperforming 92.15% of the companies in the same industry.
  • The Return On Invested Capital of HRMY (17.20%) is better than 94.76% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for HRMY is significantly above the industry average of 12.64%.
Industry RankSector Rank
ROA 15.37%
ROE 22.23%
ROIC 17.2%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • Looking at the Profit Margin, with a value of 22.48%, HRMY belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
  • In the last couple of years the Profit Margin of HRMY has grown nicely.
  • Looking at the Operating Margin, with a value of 27.32%, HRMY belongs to the top of the industry, outperforming 92.67% of the companies in the same industry.
  • In the last couple of years the Operating Margin of HRMY has declined.
  • HRMY has a Gross Margin of 77.70%. This is amongst the best in the industry. HRMY outperforms 83.77% of its industry peers.
  • In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
Industry RankSector Rank
OM 27.32%
PM (TTM) 22.48%
GM 77.7%
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HRMY is creating value.
  • HRMY has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for HRMY has been reduced compared to 5 years ago.
  • HRMY has a better debt/assets ratio than last year.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • HRMY has an Altman-Z score of 5.26. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.26, HRMY is in the better half of the industry, outperforming 76.44% of the companies in the same industry.
  • HRMY has a debt to FCF ratio of 0.57. This is a very positive value and a sign of high solvency as it would only need 0.57 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.57, HRMY belongs to the top of the industry, outperforming 96.86% of the companies in the same industry.
  • HRMY has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
  • HRMY has a Debt to Equity ratio (0.18) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 0.57
Altman-Z 5.26
ROIC/WACC1.82
WACC9.43%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.75 indicates that HRMY has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.75, HRMY perfoms like the industry average, outperforming 57.07% of the companies in the same industry.
  • HRMY has a Quick Ratio of 3.72. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
  • HRMY's Quick ratio of 3.72 is in line compared to the rest of the industry. HRMY outperforms 58.12% of its industry peers.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.72
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

9

3. Growth

3.1 Past

  • HRMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.71%, which is quite impressive.
  • HRMY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 44.61% yearly.
  • HRMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.13%.
  • HRMY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.13% yearly.
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%

3.2 Future

  • Based on estimates for the next years, HRMY will show a very strong growth in Earnings Per Share. The EPS will grow by 36.75% on average per year.
  • Based on estimates for the next years, HRMY will show a quite strong growth in Revenue. The Revenue will grow by 14.79% on average per year.
EPS Next Y31.24%
EPS Next 2Y31.22%
EPS Next 3Y28.46%
EPS Next 5Y36.75%
Revenue Next Year21.02%
Revenue Next 2Y18.62%
Revenue Next 3Y16.71%
Revenue Next 5Y14.79%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • HRMY is valuated reasonably with a Price/Earnings ratio of 9.17.
  • 91.10% of the companies in the same industry are more expensive than HRMY, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.99, HRMY is valued rather cheaply.
  • A Price/Forward Earnings ratio of 6.75 indicates a rather cheap valuation of HRMY.
  • 92.15% of the companies in the same industry are more expensive than HRMY, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, HRMY is valued rather cheaply.
Industry RankSector Rank
PE 9.17
Fwd PE 6.75
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaper than 97.38% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, HRMY is valued cheaper than 95.81% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.66
EV/EBITDA 5.82
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of HRMY may justify a higher PE ratio.
  • A more expensive valuation may be justified as HRMY's earnings are expected to grow with 28.46% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y31.22%
EPS Next 3Y28.46%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • HRMY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HARMONY BIOSCIENCES HOLDINGS

NASDAQ:HRMY (2/20/2026, 8:00:01 PM)

After market: 30.28 +1.12 (+3.84%)

29.16

-5.23 (-15.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)02-24
Inst Owners85.16%
Inst Owner Change-0.25%
Ins Owners1.63%
Ins Owner Change-61.66%
Market Cap1.68B
Revenue(TTM)825.94M
Net Income(TTM)185.68M
Analysts78.82
Price Target47.38 (62.48%)
Short Float %11.62%
Short Ratio8.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)0.59%
PT rev (3m)5.58%
EPS NQ rev (1m)0.83%
EPS NQ rev (3m)2.27%
EPS NY rev (1m)1.08%
EPS NY rev (3m)0.83%
Revenue NQ rev (1m)0.34%
Revenue NQ rev (3m)0.86%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)2.2%
Valuation
Industry RankSector Rank
PE 9.17
Fwd PE 6.75
P/S 2.03
P/FCF 5.66
P/OCF 5.64
P/B 2.01
P/tB 2.27
EV/EBITDA 5.82
EPS(TTM)3.18
EY10.91%
EPS(NY)4.32
Fwd EY14.82%
FCF(TTM)5.15
FCFY17.68%
OCF(TTM)5.17
OCFY17.72%
SpS14.34
BVpS14.5
TBVpS12.84
PEG (NY)0.29
PEG (5Y)N/A
Graham Number32.21
Profitability
Industry RankSector Rank
ROA 15.37%
ROE 22.23%
ROCE 22.91%
ROIC 17.2%
ROICexc 54.26%
ROICexgc 78.12%
OM 27.32%
PM (TTM) 22.48%
GM 77.7%
FCFM 35.95%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 0.57
Debt/EBITDA 0.6
Cap/Depr 3%
Cap/Sales 0.09%
Interest Coverage 14.73
Cash Conversion 119.28%
Profit Quality 159.9%
Current Ratio 3.75
Quick Ratio 3.72
Altman-Z 5.26
F-Score6
WACC9.43%
ROIC/WACC1.82
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y31.24%
EPS Next 2Y31.22%
EPS Next 3Y28.46%
EPS Next 5Y36.75%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
Revenue Next Year21.02%
Revenue Next 2Y18.62%
Revenue Next 3Y16.71%
Revenue Next 5Y14.79%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year37.5%
EBIT Next 3Y28.31%
EBIT Next 5Y24.08%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A

HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ

Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?

ChartMill assigns a fundamental rating of 8 / 10 to HRMY.


What is the valuation status of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.


Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?

HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.


What are the PE and PB ratios of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 9.17 and the Price/Book (PB) ratio is 2.01.


What is the earnings growth outlook for HARMONY BIOSCIENCES HOLDINGS?

The Earnings per Share (EPS) of HARMONY BIOSCIENCES HOLDINGS (HRMY) is expected to grow by 31.24% in the next year.